Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · September 26, 2024

Patients With Persistent Mild Psoriasis After Treatment With Ustekinumab Achieve Greater Improvements in Outcomes After Switching to Guselkumab

Acta Dermato-Venereologica

 

Additional Info

Acta Dermato-Venereologica
Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial
Acta Derm Venereol 2024 Sep 05;104(xx)adv41053, E Errichetti, P Wolf, S Khattri, P Gorecki, M Miller, J Jiang, C Han, B Kirby

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading